-
公开(公告)号:US11634417B2
公开(公告)日:2023-04-25
申请号:US16835702
申请日:2020-03-31
Applicant: Array BioPharma Inc.
Inventor: James F. Blake , Mark Laurence Boys , Mark Joseph Chicarelli , Adam W. Cook , Mohamed S. A. Elsayed , Jay Bradford Fell , John P. Fischer , Ronald Jay Hinklin , Yutong Jiang , Oren T. McNulty , Macedonio J. Mejia , Martha E. Rodriguez , Christina E. Wong
IPC: C07D253/06 , A61K31/53 , C07D471/04 , A61P35/00 , C07D401/14 , C07D471/10 , C07D513/10 , A61K45/06
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号:US11267818B2
公开(公告)日:2022-03-08
申请号:US17020461
申请日:2020-09-14
Applicant: Array BioPharma Inc.
Inventor: Julia Haas , Steven W. Andrews , Yutong Jiang , Gan Zhang
IPC: C07D487/04 , C07D471/04 , C07D519/00 , A61P29/00 , A61K9/00 , A61K31/519 , A61K31/5377 , A61K45/06
Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
-
3.
公开(公告)号:US20190270749A1
公开(公告)日:2019-09-05
申请号:US16415575
申请日:2019-05-17
Applicant: Array BioPharma Inc.
Inventor: Shelley Allen , Steven Wade Andrews , James F. Blake , Barbara J. Brandhuber , Julia Haas , Yutong Jiang , Timothy Kercher , Gabrielle R. Kolakowski , Allen A. Thomas , Shannon L. Winski
IPC: C07D491/048 , C07D409/14 , C07D401/14 , C07D231/52 , C07D231/56 , C07D401/04 , C07D453/02 , C07D413/12 , C07D405/12 , C07D403/14 , C07D403/04 , C07D403/02 , C07D401/12 , C07D231/54 , C07D231/40 , C07D405/14 , C07D471/08
Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
-
公开(公告)号:US20190247398A1
公开(公告)日:2019-08-15
申请号:US16170976
申请日:2018-10-25
Applicant: Array BioPharma Inc. , Loxo Oncology, Inc.
Inventor: Qian Zhao , Stacey Spencer , Yutong Jiang , Julia Haas , Charles Todd Eary
IPC: A61K31/519 , A61P35/00
CPC classification number: A61K31/519 , A61K9/0019 , A61K9/0095 , A61K31/404 , A61K31/496 , A61K47/02 , A61K47/36 , A61K47/38 , A61P35/00 , C07B2200/13 , C07C55/06 , C07C55/10 , C07C57/145 , C07C57/15 , C07C59/08 , C07C59/245 , C07C59/255 , C07C59/265 , C07C59/285 , C07C63/06 , C07C229/24 , C07C233/83 , C07C301/00 , C07C309/04 , C07C309/05 , C07C309/08 , C07C309/29 , C07C309/30 , C07C309/35 , C07D471/22 , A61K2300/00
Abstract: The present application in some embodiments provides a pharmaceutical composition comprising: and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.
-
公开(公告)号:US10323022B2
公开(公告)日:2019-06-18
申请号:US15839706
申请日:2017-12-12
Applicant: Array BioPharma Inc.
Inventor: Shelley Allen , Steven W. Andrews , James F. Blake , Kevin R. Condroski , Julia Haas , Lily Huang , Yutong Jiang , Timothy Kercher , Gabrielle R. Kolakowski , Jeongbeob Seo
IPC: C07D403/12 , A61K31/4162 , A61K31/4155 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , A61K31/4178 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , C07D491/048
Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
-
公开(公告)号:US10174027B2
公开(公告)日:2019-01-08
申请号:US15858658
申请日:2017-12-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , James F. Blake , Mark J. Chicarelli , Adam Golos , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski
IPC: C07D471/04 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/499 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D519/00
Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
-
公开(公告)号:US20180133207A1
公开(公告)日:2018-05-17
申请号:US15860894
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US09902741B2
公开(公告)日:2018-02-27
申请号:US15632187
申请日:2017-06-23
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Kevin Ronald Condroski , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Jeongbeob Seo , Hong-Woon Yang , Qian Zhao
IPC: C07D498/22 , C07D471/22 , C07D487/22
CPC classification number: C07D498/22 , A61K31/519 , C07D471/22 , C07D487/04 , C07D487/22 , C07D519/00
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
-
公开(公告)号:US09840519B2
公开(公告)日:2017-12-12
申请号:US15350888
申请日:2016-11-14
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Kevin Ronald Condroski , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Jeongbeob Seo , Hong-Woon Yang , Qian Zhao
IPC: C07D498/22 , C07D471/22
CPC classification number: C07D498/22 , A61K31/519 , C07D471/22 , C07D487/04 , C07D487/22 , C07D519/00
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
-
10.
公开(公告)号:US09809578B2
公开(公告)日:2017-11-07
申请号:US14442495
申请日:2013-11-13
Applicant: Array BioPharma Inc.
Inventor: Barbara J. Brandhuber , Yutong Jiang , Gabrielle R. Kolakowski , Shannon L. Winski
IPC: C07D403/14 , C07D401/14 , C07D403/12
CPC classification number: C07D403/14 , C07D401/14 , C07D403/12
Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
-
-
-
-
-
-
-
-
-